Daijiworld Media Network - New Delhi
New Delhi, Aug 3: Theon Pharmaceuticals has launched India's first therapy kit combining vonoprazan, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection, expanding the range of treatment options for gastrointestinal diseases in the country.
The therapy kit brings together all three medicines in a single package, offering a simplified treatment regimen for patients diagnosed with the bacterial infection, which is associated with gastritis, peptic ulcers and an increased risk of gastric cancer.
The combination is centred on vonoprazan, a potassium-competitive acid blocker (P-CAB), which provides stronger and longer-lasting acid suppression than conventional proton pump inhibitors (PPIs). Improved acid control is believed to enhance the effectiveness of antibiotics, resulting in higher H. pylori eradication rates, particularly in regions where antibiotic resistance is increasing.
According to the company, the co-packaged therapy has been developed to improve patient compliance by reducing the complexity of taking multiple medicines separately.
Conventional H. pylori treatment typically requires patients to follow a strict schedule involving acid-suppressing medication along with antibiotics. By combining all three medicines in a single therapy kit, the company expects to simplify dosing and improve adherence to the prescribed treatment.
H. pylori infection is one of the leading causes of gastritis and peptic ulcer disease and is recognised as a major risk factor for gastric cancer. Medical experts have increasingly stressed the need for more effective eradication therapies as resistance to conventional antibiotic regimens continues to rise.
Vonoprazan-based triple therapy has already been introduced in several international markets, where clinical studies have demonstrated higher eradication rates and favourable safety profiles compared with traditional proton pump inhibitor-based therapies.
Theon Pharmaceuticals said the launch reflects its focus on developing innovative pharmaceutical formulations for the Indian market. The company believes the new therapy kit will provide physicians with an additional evidence-based treatment option while supporting improved management of gastrointestinal diseases through a more convenient and patient-friendly treatment format.